investigators have suggested that heparin inhibits 18-hydroxylase, but other mechanisms are possible-for example, a non-specific toxic effect on granulosa cells, a modification of the production of adrenocorticotrophic hormone, or inhibition by the preservative chlorbutol. 315 We found no change in plasma cortisol concentrations, which probably excludes an effect on adrenocorticotrophic hormone, and decreased aldosterone concentrations without any change in plasma renin activity, which could suggest a direct effect on the glomerular zone of the adrenal gland. Neither drug contained chlorbutol.
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To our knowledge this is the first time that reductions in aldosterone concentrations have been reported in patients receiving low molecular weight heparin. The changes in aldosterone concentrations could have been increased by the age of our patients. Whatever its exact cause the effect of both standard and low molecular weight heparin could be clinically important for patients whose renin-angiotensin-aldosterone axis is inhibited by a drug, a disease, or age. As the use of low molecular weight heparin has increased rapidly, mainly because ofits ease of use and low haemorrhagic risk Thirty eight Danish patients (aged 16-60 years (median 30)) with chronically active Crohn's disease took part in the study. Patients with renal disease, urinary tract disease, or both, were excluded, as were patients receiving nephrotoxic drugs. All had '3'I hippuran renography and 5Cr-EDTA clearance performed.3 Cyclosporin was given in an initial dose of 5 0-7 5 mg/kg/day.3 Renal function was measured three times: at initial examination, before treatment was started; at a final examination, performed after a median of three months; and at a follow up examination, performed a median of four to six months after stopping the cyclosporin.
The median final T20 was significantly greater in both kidneys in patients who had received cyclosporin than in those who had received a placebo (table). Ten (48%) of the patients treated with cyclosporin and three (18%) of the patients given a placebo had a final T20 in both kidneys that was above the normal range (p= 0 1 1), whereas only a fifth of all the patients in the two groups had an initial T20 that was above the normal range. No differences in T20 were seen between the two groups at follow up. The median "Cr-EDTA clearance was lower in the 10 patients receiving cyclosporin who had an increased T20 (80 ml/min/I 73 m2 (range 33-90)) compared with the 11 patients with normal values of T20 (95 ml/min/1-73 ml (range 61-116)) (p=0011). The median plasma creatinine concentration in those with a raised T20 taking cyclosporin was higher (99 imol/l (range 70-150)) than in those with a normal T20 (p=0 023). An intraindividual comparison was made and the median increase in T20 from the initial examination to the final examination (with an average of the left and right kidney changes) was 61% (range -41% to 267%) in the group treated with cyclosporin. In comparison, the T20 of the patients who were given a placebo fell by 12% (range -75% to 43%) (p=0O0062). The decrease in 5'Cr-EDTA clearance was larger (median fall of 23%, range -39% to 6%) in patients in whom the T20 had increased above the median increase in T20 (61%) than in the remaining patients treated with cyclosporin (fall of 1%, range -6% to 48%) and all the patients receiving a placebo (1%, range -10% to 27%) (p= 0-015).
Comments
Because the renal clearance of hippuran occurs predominantly by tubular uptake and secretion, the increased T20 most probably resulted from a tubulopathy. Recent studies have suggested, however, that cyclosporin is not directly toxic to the tubular cells but that the tubulopathy is secondary to primary changes in renal haemodynamics.' We found no difference in the final 5Cr-EDTA clearance, and, though the exact p value suggested a type II error, no significant change was seen when the patients treated with cyclosporin served as their own controls. Furthermore, no changes in the time taken to achieve maximal activity on the renograms were found. We therefore concluded that in the short term low dose cyclosporin does not interfere appreciably with renal haemodynamics. Nevertheless, the finding of increased values of T20 in the patients treated with cyclosporin suggests that the tubular cells might be sensitive to small, and thus by the methods used here not readily detectable, changes in renal blood flow. This is in keeping with a slight, but significant, increase in the median plasma creatinine concentration of the group treated with cyclosporin ( 
